DNA methylation profiling predicts postsurgical regrowth in SF1-lineage nonfunctioning pituitary neuroendocrine tumors
DNA methylation profiling identifies biologically and clinically distinct NFPitNET subgroups, particularly within the SF1 lineage, and may enhance prediction of recurrence risk. Prospective validation and demonstration of clinical utility are warranted to support integration into precision management workflows.
Authors
- Henning B. Boldt (ORCID: https://orcid.org/0000-0003-0569-0656)
- Christopher Powell
- Marianne Andersen (ORCID: https://orcid.org/0000-0002-4603-9504)
- Ana Valeria Castro (ORCID: https://orcid.org/0000-0003-1625-0015)
- Morten Winkler Møller (ORCID: https://orcid.org/0000-0001-5677-0969)
- Grayson Herrgott
- Frantz Rom Poulsen (ORCID: https://orcid.org/0000-0001-5715-6901)
- Bo Halle (ORCID: https://orcid.org/0000-0001-9930-4490)
- Jeanette Krogh Petersen (ORCID: https://orcid.org/0000-0002-5093-5985)
- Christian Bonde Pedersen (ORCID: https://orcid.org/0000-0003-3761-0446)
Institutions
- Henry Ford Health System (US)
- University of Southern Denmark (DK)
- Odense University Hospital (DK)
- IPS Research (United States) (US)
- Michigan State University (US)
Publication Details
- Journal
- Neuro-Oncology
- Published
- 2025-12-08
- DOI
- https://doi.org/10.1093/neuonc/noaf269
- Primary Topic
- Pituitary Gland Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00